Merck & Co., Inc.
MRK · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.29 | -0.90 | 0.30 | 0.92 |
| FCF Yield | 3.26% | 1.28% | 0.52% | 0.99% |
| EV / EBITDA | 34.52 | 35.11 | 34.46 | 48.78 |
| Quality | ||||
| ROIC | 7.72% | 5.29% | 5.60% | 4.26% |
| Gross Margin | 81.92% | 77.50% | 77.98% | 75.50% |
| Cash Conversion Ratio | 1.35 | 0.74 | 0.49 | 0.92 |
| Growth | ||||
| Revenue 3-Year CAGR | 2.69% | 2.95% | 3.37% | 2.67% |
| Free Cash Flow Growth | 170.26% | 115.78% | -53.36% | -70.46% |
| Safety | ||||
| Net Debt / EBITDA | 3.44 | 4.27 | 3.58 | 4.39 |
| Interest Coverage | 31.75 | 18.20 | 18.97 | 13.26 |
| Efficiency | ||||
| Inventory Turnover | 0.48 | 0.54 | 0.55 | 0.63 |
| Cash Conversion Cycle | 129.31 | 136.00 | 126.03 | 106.93 |